| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
- Intracellular lipases [1][2]
|
|---|---|
| ln Vitro |
- Trierucin (trierucoylglycerol) was not cleaved by lipases in heart homogenates. After 60 minutes of incubation, less than 5% of Trierucin was hydrolyzed, while triolein (control substrate) was hydrolyzed by 65±4% under the same conditions [1]
- It was efficiently hydrolyzed by lipases in skeletal muscle homogenates: 60-minute incubation resulted in 58±3% hydrolysis of Trierucin [1] - It could be synthesized from 1,2-dierucoylglycerol by lipases/transferase in microspore-derived embryo homogenates of Brassica napus. The synthesis yield reached 42±3% after 4 hours of incubation [2] |
| Enzyme Assay |
- Lipase hydrolysis assay (heart and skeletal muscle): Heart and skeletal muscle tissues were homogenized in buffer to prepare enzyme extracts. Trierucin (or triolein as control) was added as substrate, and the mixture was incubated at 37°C for 60 minutes. The hydrolysis product (free fatty acids) was quantified by titration or chromatographic method to evaluate lipase activity [1]
- Trierucin synthesis assay (Brassica napus embryo): Microspore-derived embryos were homogenized in reaction buffer containing 1,2-dierucoylglycerol (substrate) and acyl-CoA. Trierucin synthesis was detected by thin-layer chromatography (TLC) after 4 hours of incubation at 25°C, and the product was quantified by densitometry [2] |
| Toxicity/Toxicokinetics |
- The inability of cardiac lipases to break down erucic acid glycerides may lead to erucic acid lipid deposition in myocardial tissue, as undegraded erucic acid glycerides accumulate in cardiomyocytes [1]
|
| References |
|
| Additional Infomation |
Glyceryl trierucic acid has been investigated for the treatment of adrenoleukodystrophy.
- Trierucic acid is a triglyceride composed of three erucic acid (C22:1) chains esterified onto glycerol [1][2] - Its metabolic properties are tissue-specific: skeletal muscle lipases can hydrolyze it, while cardiac lipases lack this activity [1] - It can be used as a substrate for studying tissue-specific lipase activity and is involved in the biosynthesis of stored lipids in the embryo of Brassica napus [2] |
| Molecular Formula |
C69H128O6
|
|---|---|
| Molecular Weight |
1053.75102
|
| Exact Mass |
1052.97
|
| CAS # |
2752-99-0
|
| PubChem CID |
5463075
|
| Appearance |
White to off-white solid powder
|
| Density |
0.909g/cm3
|
| Boiling Point |
909.6ºC at 760mmHg
|
| Melting Point |
32 °C
|
| Flash Point |
321.8ºC
|
| Vapour Pressure |
6E-34mmHg at 25°C
|
| Index of Refraction |
1.476
|
| LogP |
22.778
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
65
|
| Heavy Atom Count |
75
|
| Complexity |
1190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC
|
| InChi Key |
XDSPGKDYYRNYJI-IUPFWZBJSA-N
|
| InChi Code |
InChI=1S/C69H128O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52-55-58-61-67(70)73-64-66(75-69(72)63-60-57-54-51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)65-74-68(71)62-59-56-53-50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h25-30,66H,4-24,31-65H2,1-3H3/b28-25-,29-26-,30-27-
|
| Chemical Name |
2,3-bis[[(Z)-docos-13-enoyl]oxy]propyl (Z)-docos-13-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~32.5 mg/mL (~30.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.08 mg/mL (1.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.08 mg/mL (1.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.08 mg/mL (1.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9490 mL | 4.7450 mL | 9.4899 mL | |
| 5 mM | 0.1898 mL | 0.9490 mL | 1.8980 mL | |
| 10 mM | 0.0949 mL | 0.4745 mL | 0.9490 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
